Acrongenomics Partner Molecular Vision Successful in Winning Prestigious Award from the UK Royal Society

Acrongenomics Inc. (OTCBB: AGNM) announces that its partner Molecular Vision Ltd. has been successful in winning the 250,000 GBP Royal Society Brian Mercer Award for Innovation 2007. This is a prestigious award from the UK's Royal Society to develop low-cost, high throughput, reel to reel, manufacturing techniques for plastic electronics.

Acrongenomics and Molecular Vision's medical diagnostic products use organic semiconductors to generate and detect light. This is the highly sophisticated technology used in the chemiluminescence and fluorescence demonstrators presented to a selective technical audience recently. This award will allow Molecular Vision to further develop the technology enabling it to significantly drive down the cost of these medical point-of-care technology devices for the global market.

"Awards of this magnitude give additional recognition to our scientific work, establishing the great potential of our technology to change the way we live, and make a great contribution to the global medical community," said Plato Tzouvalis President of Acrongenomics.

About the UK Royal Society
The Royal Society is the world's oldest scientific academy in continuous existence, and has been at the forefront of enquiry and discovery since its foundation in 1660.
The backbone of the Society is its Fellowship of the most eminent scientists of the day, elected by peer review for life and entitled to use FRS after their name. There are currently more than 60 Nobel Laureates amongst the Society's approximately 1400 Fellows and Foreign Members.
Throughout its history, the Society has promoted excellence in science through its Fellowship and Foreign Membership, which has included Isaac Newton, Charles Darwin, Ernest Rutherford, Albert Einstein, Dorothy Hodgkin, Francis Crick, James Watson and Stephen Hawking. The Society is independent of government, as it has been throughout its existence, by virtue of its Royal Charters. In 1663, The Royal Society of London for the Improvement of Natural Knowledge was granted its Arms and adopted the motto "Nullius in verba", an expression of its enduring commitment to empirical evidence as the basis of knowledge about the natural world.

About Molecular Vision Ltd.
Molecular Vision is a spin-out company of Imperial Innovations Ltd. The company was founded by three Imperial College London researchers - Prof. Donal Bradley, Prof. Andrew de Mello and Dr. John de Mello - in 2002 in order to meet a clearly defined demand in the medical diagnostics, biosensors and analytical instrumentations markets: the need for miniaturized chemical and biological detectors offering high sensitivity and functionality at low cost. The company has directly addressed this market demand by inventing a novel method for optical detection based on recent advances in organic electronics and light emitting diodes combined with microfluidics technology. The company has mainly focused on applying its technology to the medical diagnostics markets. Molecular Vision recently signed a major development contract with Acrongenomics Inc. to jointly exploit and commercialize the technology.

About Acrongenomics Inc.
Acrongenomics Inc. is a publicly traded company that focuses on investing in and commercializing novel technology platforms concerning the Life Sciences sector. Acrongenomics brings novel and realistic concepts to market by transforming scientific innovations into tangible, consumer-orientated applications.